IGF-1 LR3 is not approved mecasermin
Long R3 IGF-I is a laboratory-engineered analogue of insulin-like growth factor 1 with reduced affinity for IGF-binding proteins.[1] It is structurally and regulatorily distinct from mecasermin (Increlex), the approved recombinant human IGF-1 medicine.
Evidence is preclinical and indirect
Laboratory studies describe altered binding-protein interactions and biological potency for Long R3 IGF-I.[1] Teloryx found no controlled human clinical trial establishing IGF-1 LR3 for muscle gain, fat loss, recovery, healing, anti-aging, or any disease. Evidence about native IGF-1, IGF-1 gene expression, or mecasermin cannot be transferred to this analogue.
Related-drug risks do not create an LR3 safety profile
The current Increlex label includes hypoglycemia, hypersensitivity, intracranial hypertension, lymphoid-tissue hypertrophy, orthopedic complications, and malignant-neoplasia warnings.[2] Those are product-label findings for mecasermin, not measured incidence estimates for IGF-1 LR3. For LR3, human pharmacokinetics, dose-response, interactions, pregnancy effects, product quality, and long-term safety are unknown.
Regulatory and sport status
IGF-1 LR3 is not FDA-approved. Increlex is approved only for specified pediatric growth-failure conditions and does not validate LR3.[2] IGF-1 and its analogues are prohibited in tested sport.[3] Teloryx does not publish an LR3 dose, cycle, stack, or reconstitution recipe.